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AbstrACt
Introduction Sarcomas are rare tumours of connective 
tissue. The exact overall incidence of sarcomas is 
unknown due to diagnostic difficulties and the various 
histological subtypes (over 80 subtypes). However, the 
apparent increasing incidence of sarcomas suggests 
environmental causes such as pesticides. Except 
for some specific factors (ie, ionising radiation, vinyl 
chloride, dioxin and genetic predispositions) the scientific 
knowledge on the aetiology of sarcomas is sparse and 
inconsistent. France is a particularly appropriate country 
to set up a study investigating the causes of sarcoma 
occurrence due to the French organisation in treatment 
and care of sarcoma patients, which is highly structured 
and revolved around national expert networks. The 
main objective of the ETIOlogy of SARcomas (ETIOSARC) 
project is to study the role of lifestyle, environmental 
and occupational factors in the occurrence of sarcomas 
among adults from a multicentric population-based 
case–control study.
Methods and analysis Cases will be all incident 
patients (older than 18 years) prospectively identified in 
15 districts of France covered by a general population-
based cancer registry and/or a reference centre in 
sarcoma’s patient care over a 3-year period with an 
inclusion start date ranging from February 2019 to 
January 2020 and histologically confirmed by a second 
review of the diagnosis. Two controls will be individually 
matched by sex, age (5 years group) and districts of 
residence and randomly selected from electoral rolls. 
A standardised questionnaire will be administered by a 
trained interviewer in order to gather information about 
occupational and residential history, demographic and 
socioeconomic characteristics and lifestyle factors. 
At the end of the interview, a saliva sample will be 
systematically proposed. This study will permit to validate 
or identify already suspected risk factors for sarcomas 
such as phenoxyherbicides, chlorophenol and to generate 
new hypothesis to increase our understanding about 
the genetic and environmental contributions in the 
carcinogenicity process.
Ethics and dissemination The present study is promoted 
by the French National Institute of Health and Medical 
Research (identification number C17-03). This study 
received National French Ethic committee (CPP Sud 
Méditerrannée I) approval (identification number 18-31) 
and French Data Protection Authority (CNIL) approval 
(identification number 918171). Results of this study will 
be published in international peer-reviewed journals. 
Technical appendix, statistical code and dataset will be 
available in the Dryad repository when collection data are 
completed.
trial registration number NCT03670927.
IntroduCtIon
Sarcomas are a heterogeneous group of rare 
malignant tumours of connective tissues. 
Besides multiple and complex histology 
strengths and limitations of this study
 ► All newly diagnosed patients will be ascertained 
through a systematic review of the diagnostic by 
an expert pathologist within French sarcomas 
networks.
 ► Prospective inclusion of >2000 population-based 
patients which will allow to perform analysis by his-
tological subtypes.
 ► Collection of various exposure data using face-to-
face administered standardised questionnaire by 
trained interviewers. Additionally, saliva samples 
will be collected.
 ► Possible low participation rate of population controls.
 ► Retrospective collection of data and over a long pe-
riod of time.
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(approximatively over 80 subtypes), these tumours can 
occur in almost any anatomic site. It is usual to distinguish 
bone sarcomas (osteosarcomas and chondrosarcomas) 
from soft-tissue sarcomas (muscles, joints, fat, nerves, skin 
tissues and blood vessels) and visceral sarcomas. Even 
though it accounts for <1% of adult cancers, sarcoma is 
one of the most frequent cancer types in young adults.1 
Based on statistics of the Surveillance, Epidemiology and 
End Results programme from 2008 to 2012, median age 
at diagnosis for soft-tissue sarcomas and bones sarcomas 
were 59 and 42 years of age, respectively, and median age 
at death was 65 years old for soft-tissue sarcomas and 59 
years old for bones sarcomas.2 
At the genetic level, sarcomas can be split into two 
large categories based on the rearrangement level of 
the genome. On the one side sarcomas with very simple 
genetics (50% of all sarcomas) based on point muta-
tion (gastrointestinal stromal tumour (GIST), desmoïd 
tumour) or a specific and recurrent translocation (Ewing, 
Synovial sarcoma, Myxoïd liposarcoma and so on); and 
on the other side, sarcomas with a very complex genetics 
(50% of all sarcomas, leiomyosarcoma, angiosarcoma, 
undifferentiated pleomorphic sarcoma and so on).3
The incidence of sarcomas has been very imperfectly 
estimated due to both diagnostic confusion with carci-
nomas of the same organ and the variety of localisa-
tion of these tumours. Thirty per cent of sarcomas are 
misclassified at initial diagnosis.4 Cancer incidence is 
often reported by site possibly leading to an under-es-
timation of incidence for some subtypes. In France, 
the world age-standardised incidence rates of overall 
sarcomas was estimated at 4.8 per 100 000 inhabitants per 
year5 and soft-tissue sarcoma’s incidence, which account 
for >50% of sarcomas patients was estimated at 3.3 per 
100 000 inhabitants per year.6 While some authors did 
not confirm an incidence increase over last years,7 others 
reported a statistically significant raise of the incidence of 
sarcomas8 9 leading to the hypotheses of an implication 
of environmental factors in the aetiology of this cancer. 
However, the role of diagnostic and reporting practice 
cannot be ruled out.
The various histological subtypes, various anatomical 
sites as well as the rarity of the disease make the aeti-
ology of this cancer difficult to study.1 Some studies have 
attempted to investigate the role of some environmental 
factors; however, results are often inconclusive or incon-
sistent from one study to another. Thus, to date, it is 
impossible to draw strong conclusions on the aetiology 
of sarcomas from existing studies. Indeed, there are 
some methodological considerations to explain discrep-
ancies between studies: sample sizes are often limited 
leading to insufficient power to detect small but relevant 
increases in risk. As a consequence, sarcomas are studied 
as a single outcome and not by histological subtypes; 
at most they are segregated into bone sarcomas and 
soft-tissue sarcomas. Such analyses support the strong 
hypothesis that the same aetiology is shared between 
each subtype and each site. The inclusion periods of 
patients are usually old and ascertainment of patients 
may be incorrect. Indeed, a second expert review of 
diagnosis is essential to correctly classify sarcoma’s 
tumours.10 Diagnostic procedures have been refined 
in expert centres during the last several years with the 
inclusion of new genetic and molecular data leading to 
a better understanding and definition of tumours. As 
a consequence, a new WHO classification of soft-tissue 
tumours was published in 2013.11
From International Agency for Research on 
Cancer (IARC) evaluation, the strongest evidence for 
environmental cause is for ionising radiations (including 
radiotherapy) for both soft tissue and bone sarcomas that 
are classified in group 1 as carcinogenic to humans.12 
Convincing evidence also exists for linking vinyl chlo-
ride to the occurrence of a specific type of sarcoma (liver 
angiosarcoma). This conclusion arises from consistent 
observations in vinyl chloride industry that conducted 
IARC to classify this agent also in group 1 as carcinogenic 
in humans.13 The dioxin 2,3,7,8-tetrachlorodibenzo-p-di-
oxin, released to the environment during the combustion 
of fossil fuels and wood, and waste incineration has also 
been classified carcinogenic by the IARC, with evidence 
for soft-tissue sarcoma.13
Because epidemiological studies have consistently 
demonstrated higher mortality and incidence rates from 
soft-tissue sarcomas in farmers, specific attention has 
been paid to the potential role of pesticide exposure in 
the occurrence of these tumours.14 Several case–control 
studies assessed the relationship between herbicide and 
chlorophenol with soft-tissue sarcoma risk but results 
varied from no association to a strong relationship for 
exposed populations.15–20 Discrepancies between studies 
may be due in part to the low statistical power due to 
small sample sizes but most importantly to difficulties in 
exposure assessment. Indeed, disentangling the various 
contributions of chlorophenols, herbicides and dioxins 
is complicated because chlorophenols are used in the 
production of herbicides and dioxins are also a contami-
nant in herbicides production.
Some studies have also suggested that other pesticides 
than phenoxys could play a role in the occurrence of 
sarcomas. Increased risk of soft-tissue sarcoma have been 
observed in a cohort of workers in an organochlorine 
production plant,21 in a population living in the vicinity 
of an organochlorinated-compounds factory in Spain22 
and also in a case–control study in Canada exploring 
some specific pesticides.23 This last study found signifi-
cant associations with two insecticides: aldrin (OR=3.71, 
1.00 to 13.76) and diazinon (OR=3.31, 1.78 to 6.23) and 
a trend with formaldehyde (OR=2.07, 0.94 to 4.56). A 
case–control study in Kansas failed to find associations 
with pesticides used on crops, including herbicides24 but 
found an increased risk with the use of insecticides to 
animals,25 higher for farmers who mixed or applied them-
selves and for those who did not use any protective equip-
ment, also more pronounced for so-called ‘fibrous’ and 
‘myomatous’ sarcomas. A European study on risk of adult 
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bone sarcomas also found an association with pesticides 
that was similar for insecticides and herbicides.26
Other occupational exposures have also been explored 
and, besides farming, some industries have been asso-
ciated in some studies with elevated risks of soft-tissue 
sarcomas: gardeners, meat packers, sawmill workers, 
machinists and ground maintenance workers.27–29 
Exploring specific chemicals or agents, positive associ-
ations have been found with wood dust,28 radium27 and 
1–3 butadiene30 for soft-tissue sarcoma. A multicentre 
case–control study in seven European countries specif-
ically focused on bone sarcomas found increased risks 
among blacksmiths, toolmakers, machine-tool operators 
and construction workers.26
Besides occupational factors, few studies investigated 
other environmental factors related to lifestyle, including 
the potential role of female hormones, tobacco smoke, 
alcohol, nutrition, fluoride in drinking water and body 
mass index. These studies reported inconclusive or incon-
sistent results with the exception of viruses like the HIV 
and human herpes virus 8 for Kaposi’s sarcoma.1
Finally, while there is increased evidence regarding 
genetic determinants of sarcoma risk,31 and growing 
evidence that gene × environment (G×E) interactions 
are determinants of development and progression of 
complex disease,32 to date, there are no data related 
to such G×E interactions with regards to sarcoma risk. 
However, studying G×E interactions may help to iden-
tify susceptible groups of individuals which is essential to 
better target prevention programmes or to develop preci-
sion medicine.33
Several hypotheses have been studied regarding the 
aetiology of sarcomas. Nevertheless, the methodological 
limitations such as diagnosis certification, small sample 
sizes, exposure assessment methodology and the analysis 
strategies that do not distinguish the various histolog-
ical subtypes making the hypothesis that the aetiology 
is homogeneous across all histological subtypes prevent 
any definite conclusions. There is a clearly identified 
need to further investigate the aetiology of sarcomas with 
improved study designs including a systematic centralised 
diagnosis review by a second expert, increased sample 
sizes, more refined exposure assessment methods and 
also a biological component to increase our under-
standing of biologic mechanisms of carcinogenesis and 
to study the interaction between the genetic and environ-
ment component.
France is a particularly appropriate country to set up 
such study due to the French organisation in treatment 
and care of sarcoma patients around three national 
networks labelled by the French National Cancer Institute: 
the network of reference for soft-tissue sarcoma pathology 
(RRePS: https:// rreps. sarcomabcb. org/ home. htm), the 
network of reference for bone sarcoma pathology (ResOs: 
https:// resos. sarcomabcb. org/ home. htm) and the clin-
ical sarcoma network (NetSarc: https:// netsarc. sarcom-
abcb. org/ home. htm). The objectives of RRePS and ResOs 
are to ensure systematic and free secondary reviews for all 
new diagnoses of soft tissue and visceral sarcomas, GIST, 
desmoid tumours and bone sarcomas across the whole of 
France, and to facilitate access to molecular biology anal-
yses, collection of samples for biological resource centres, 
to participate in research and clinical trials, to draft good 
clinical practice guidelines for professionals and informa-
tion documents for patients and to organise continuing 
education and information for patients.34 The NetSarc 
clinical network for sarcoma is the clinical network of the 
French Sarcoma Group dedicated to clinical patient care. 
NetSarc is managed by three sites (Centre Leon Berard in 
Lyon, Institut Bergonie in Bordeaux and Institut Gustave 
Roussy in Villejuif) working closely with 25 expert regional 
centres, ensuring good coverage of the whole French 
territory.35 Besides, the French population-based cancer 
registries are organised in a collaborative network named 
Francim. The main objectives of this network are to coor-
dinate the 14 general cancer registries and 11 special-
ised cancer registries that exhaustively register all newly 
diagnosed and confirmed cancer patients according to 
international procedures, to harmonise patients registra-
tion and data quality, to provide epidemiological indica-
tors (incidence, survival, prevalence) and to coordinate 
epidemiological and surveillance research on cancer.
The main objective of the ETIOSARC study is to assess 
the role of lifestyle, environmental and occupational 
factors in the occurrence of sarcomas among adults from 
a multicentre population-based case–control study.
Specific objectives are:
 ► To identify environmental risk factors for sarcomas as 
a whole and for the most frequent subtypes.
 ► To investigate the interactions between gene poly-
morphisms and environmental exposures in sarcoma 
susceptibility.
 ► To assess whether some specific genetic characteris-
tics of sarcoma’ tumours are associated with environ-
mental exposures.
We will also explore the feasibility of classifying sarcomas 
by genetics types (simple vs complex genomic profile) 
instead of by histological subtypes as part of the objective 
of identifying environmental risk factors.
MEthods And AnAlysIs
study design
The ETIOSARC study is a prospective multicentre popu-
lation-based case–control study. This study is restricted to 
French geographical areas (further called districts) that 
meet at least one of these four criteria (figure 1):
 ► Criteria 1: districts covered by both a general cancer 
registry and a French Sarcoma Group (GSF-GETO) 
expert centre from the sarcoma reference network.
 ► Criteria 2: districts including a coordinator centre of 
any of the RRePS/NetSarc networks.
 ► Criteria 3: districts covered by a general cancer registry 
,that is, expected to register >50 patients per year.
 ► Criteria 4: districts adjacent to districts meeting 
criteria 1 and covered by a general cancer registry.
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In total, 15 districts meet one of the four criteria, which 
represent 17 813 937 inhabitants, ~27% of the French 
population (2019 estimations from the national institute 
of statistics and economic studies, Insee). Eight districts 
meet criteria 1 (Gironde, Hérault, Haute-Vienne, Loire 
Atlantique, Calvados, metropolitan area of Lille, Bas-Rhin 
and Doubs), two districts meet criteria 2 (Rhône and 
Val-de-Marne); three districts meet criteria 3 (Isère, 
Haut-Rhin and Poitou-Charentes) and two districts meet 
criteria 4 (Manche, Vendée).
Since sarcomas are rare tumours, this study has to be 
multicentric. Indeed, from general cancer registry data 
and RRePS overall incidence data, considering a patients’ 
response rate of 70%, and considering that ~90% of 
newly diagnosed patients will benefit from a systematic 
secondary review of diagnosis, it is expected to include 
718 incident patients per year from these 15 districts, 
corresponding to a total sample size of 2154 patients from 
a 3-year recruitment (table 1). The study is planned to 
start in April 2019 and to end in April 2022.
study population
Cases definition and recruitment modalities
Cases are defined as all incident patients with a diagnosis 
of primary sarcoma and histologically confirmed by an 
expert pathologist of the RRePS or ResOs networks in the 
15 districts of France participating to this study.
Inclusion criteria are:
 ► Patients diagnosed in the previous 6 months from 
identification with a primary and histologically 
confirmed malignant sarcoma including soft-tissue, 
visceral and bone sarcomas as defined by the WHO 
classification of bones and soft tissue sarcoma, fourth 
edition, 2013.36
 ► Diagnosed over a 3-year period with an inclusion 
start date ranging from the 1 February 2019 to the 
1 January 2020 depending on the districts.
 ► Living in 1 of the 15 districts participating to the study 
at the time of diagnosis.
 ► At least 18 years old at diagnosis.
 ► Agreed to participate to the study with a signed 
informed consent.
Non-inclusion criteria are:
 ► Patients with a known genetic predisposition to 
sarcoma such as Li-Fraumeni syndrome, retinoblas-
toma syndrome, neurofibromatosis.
 ► Kaposi’s’ sarcoma.
 ► Protected adults’ patients (aged of at least 18 years 
old) under guardianship by court order.
Patients will be recruited by specifically trained clinical 
research associate (CRA). In districts where a general 
cancer registry is active, the process of identifying incident 
sarcoma patients is well defined, which warrants the effi-
ciency and exhaustiveness of the recruitment. However, 
poor survival for some cancer patients will not allow to 
rely on routine inclusion procedure and the registries 
will implement a rapid patient ascertainment procedure 
to minimise the delay between diagnosis and enrolment 
and interview. Patients will be identified from pathology 
laboratories and multidisciplinary sarcoma tumour board 
(including sarcoma, gynaecological, digestive, skin and 
bone tumour board). CRA will regularly contact laborato-
ries and hospitals (within a 3-month window) to identify 
Figure 1 Districts covered by the ETIOSARC study. Map was created with R packages maptools, maps, raster and mapdata.
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newly diagnosed sarcoma patients and to collect asso-
ciated reports. The CRA will retrieve the clinical file in 
order to check inclusion and non inclusion criteria and to 
collect names and addresses of eligible patients and their 
physicians. Then, the CRA will contact the patients’ physi-
cians in order to gather their clinical advice to include 
their patients in the study. In case of agreement, the CRA 
will contact the patients and ask them to participate. In 
case of oral agreement, he/she will arrange an inter-
view to collect written consent and administer detailed 
questionnaire.
In Rhône and Val de Marne where no general cancer 
registry exists, the process of identifying incident sarcoma 
patients will largely rely on the existence of a sarcoma 
reference network coordination centre to facilitate the 
identification of new patients.
Regardless of the district, the diagnosis of all included 
patients will be systematically ascertained by an expert 
pathologist within the RRePS and ResOs networks 
following a standard procedure.
On a regular basis (at least once a month), the list of 
incident patients included in the RRePS/ResOS/NetSarc 
networks will be extracted from the shared databases. 
The list of patients identified by registries will be merged 
with the list of patients included in the RRePS/ResOS/
NetSarc networks by the pathology sample reference 
number in order to collect diagnosis confirmation and to 
identify new but missed incident patients.
Controls selection
Two control subjects per patient will be randomly selected 
from the French general population using electoral rolls 
and individually matched to patient by age (by 5-year age 
group), sex and residential area (French department).
Inclusion criteria are:
 ► Subjects registered within the electoral rolls.
 ► At least 18 years old at interview.
 ► Living in 1 of the 15 districts participating to the study 
at the time of interview.
 ► Agreed to participate to the study with a signed 
informed consent.
Non-inclusion criteria are:
 ► Subject previously diagnosed with a primary and histo-
logically confirmed malignant sarcoma including soft-
tissue, visceral and bone sarcomas as defined by the 
Table 1 Total number of expected patients includes in the ETIOSARC study over a 3-year recruitment
Expected number 
of new sarcoma 
patients/year*
Expected number 
of confirmed 
patients/year†
Expected number 
of interviewed 
patients/year‡
Expected total 
number of included 
patients§
Criteria 1: districts covered by both a general cancer registry and a French Sarcoma Group (GSF-GETO) expert centre from the 
sarcoma reference network
  Gironde 120 108 76 228
  Hérault 86 77 54 162
  Haute-Vienne 23 21 15 45
  Calvados 50 45 31 93
  Loire-Atlantique 98 88 62 186
  Metropolitan area of Lille 48 43 30 90
  Bas-Rhin 90 81 57 171
  Doubs 42 38 27 81
Criteria 2: districts including a coordinator centre of any of the RRePS/NetSarc networks
  Rhône 116 104 73 219
  Val de Marne 68 61 43 129
Criteria 3: districts covered by a general cancer registry, that is, expected to register >50 patients per year
  Isère 89 80 56 168
  Haut-Rhin 56 50 35 105
  Poitou-Charentes 167 150 105 315
Criteria 4: districts adjacent to districts meeting criteria 1 and covered by a general cancer registry
  Vendée 51 46 32 96
  Manche 34 31 22 66
  Total 1138 1023 718 2154
*Estimation from general cancer registry data (except for Rhône et Val de Marne, estimation from RRePS data).
†Estimation with a systematic secondary review a diagnostic confirmation for 90% of patients.
‡Estimation with a response rate of 70%.
§Over a 3-year study.
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WHO classification of bones and soft tissue sarcoma, 
fourth edition, 2013.
 ► Protected adults’ patients (aged of at least 18 years 
old) under guardianship by court order.
Controls will be recruited according to an incidence 
density sampling procedure which will guarantee the 
recruitment of controls from the same source population 
as patients. The selection of controls and the recruitment 
of patients will take place simultaneously. Every time a 
patient will be diagnosed and identified, two controls will 
be randomly selected at that time from the electoral rolls 
of the same district as the patient district of residence. For 
each patient, a list of 20 potential controls with the same 
age (within a 5-year age group) and sex as the patients will 
be constituted and randomly selected in order to account 
for potential refusal. Calls to contact potential controls 
will be centralised and will be made by an investigator 
specifically trained to better understand the objectives 
of the study. Potential controls from the constituted list 
will be contacted one after the other until identifying two 
controls per case agreeing to participate to the study. First, 
this investigator will try to retrieve the phone number of 
the first potential control on the list and will contact him/
her in order to gather his/her agreement to participate 
in this study. After five calls made at different schedules 
(eg, in the evening on weekdays), if the potential control 
could not be reached, the investigator will send an 
information letter containing a reply coupon indicating 
phone number and schedule at which the person could 
be reach. If the reply coupon is not returned, or after 10 
calls made at the phone number and the schedule indi-
cated on the reply coupon, the first potential control will 
be considered as unreachable and then, the same proce-
dure will be applied for the second potential control on 
the list and so on until two controls per patient agreed to 
participate to the study.
For each control agreeing to participate, an appoint-
ment will be made to collect written consent and to 
administer detailed questionnaire by a CRA.
All participants will give their informed written consent 
to participation, in line with French ethical guidelines.
data collection
Data will be collected in a three-step procedure and 
from subjects themselves: (1) the interviewer will contact 
subjects by phone and ask them to participate in the 
study; (2) if the subject has agreed to participate, an 
appointment will be made and a consent form as well as 
a self-administered questionnaire will be sent by mail to 
each subject. This self-questionnaire will permit to gather 
the complete occupational history (for each job held for 
at least 6 months) and residential history (for each place 
occupied for at least 1 year); (3) during a face-to-face 
interview, the trained interviewer will check (complete 
if necessary) and supplement the self-administered 
questionnaire by a specific questionnaire with questions 
about demographic and socioeconomic characteristics, 
occupations of spouse and parents, leisure-time activities, 
reproduction, medical history, family history of cancer, 
diet, lifestyle factors such as tobacco smoking and alcohol 
consumption. The specific questionnaire will also collect 
additional occupational and residential information such 
as work tasks, work places, materials handled for each job 
held for at least 6 months and description of the environ-
ment of each residence places.
At the end of the interview, subjects (both patients 
and controls) will be invited to provide a saliva sample in 
order to obtain germline DNA.
In case of refusal to participate and if the subject agreed, 
data on the last occupied job and educational level will 
be collected in order to assess the potential selection bias 
that might occur due to the specific profile of non-re-
spondent subjects.
To ensure consistency in data collection, all CRA will be 
trained in the completion of the questionnaire and will 
detain a field guide of completion. Additionally, phone 
meetings involving all CRA will take place each month in 
order to deal with recurring problems in the completion 
of the questionnaire and to ensure homogeneity in data 
collection between all CRA. Moreover, these meetings will 
help maintain CRAs’ motivation and level of training.
The completeness of questionnaires and the quality of 
interviews will be routinely checked. All questionnaires 
will be scanned in order to facilitate storage and possible 
return to the questionnaires to allow quality checks.
biological sampling and storage
Each participant will be asked to provide a salivary sample 
in order to obtain germline DNA. Salivary samples will 
be collected by the subjects themselves under instruc-
tions from the CRA, using Genefix saliva DNA collection 
kit. After collection, samples will be sent at the Biolog-
ical Resources Centre of the Bordeaux hospital university 
centre ‘Bordeaux Biothèque Santé’ for storage (NFS-96900 
certification, BBMRI-ERIC ID: FR_BB-0033–00094).
determination of the sample size
The main objective of this study is to examine the asso-
ciation between environmental exposures (including 
general environment, occupational environment and 
lifestyle) and risk of sarcoma occurrence. Since our defi-
nition of environmental exposures is very broad, we have 
based our sample size calculation on various scenarios of 
exposure prevalence, from 5% (relevant for domestic, 
environmental but also some occupational exposures 
such as farmer in the general population) to 20% (rele-
vant for some occupational exposures such as fibres). For 
a total sample size of 2000 patients and a 1:2 individu-
ally matched design, considering a statistical power of 
80% at a significance level of 5%, the minimum detectable 
OR will be 1.39 and 1.21 under an exposure prevalence of 
5% and 20%, respectively. Considering subtypes analyses, 
the four main histological types are GIST, liposarcoma, 
leiomyosarcoma and unclassified sarcoma, which account 
for 18%, 15%, 11% and 16% of sarcomas, respectively. 
Considering a sample size of 300 patients, the minimum 
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detectable OR will be 2.21 and 1.61 under an exposure 
prevalence of 5% and 20%, respectively. Typically in 
environmental epidemiology, the relative increases in 
disease risks due to environmental exposures are usually 
low around 1.5, thus, it is essential to recruit a minimum 
of 2000 patients in order to be able to perform subtype 
analyses.
statistical analysis
Relationship between patient/control status and each 
exposure variable and 95% CI will be individually esti-
mated using conditional logistic regression models. If 
necessary, a multilevel logistic model will be implemented 
in order to take into account the data variability due to 
the multicentre design and the various CRA that will 
administer the questionnaires (even if each CRA will be 
trained to the administration of the questionnaires).
As previously mentioned, previous case–control studies 
had limited sample sizes leading to insufficient power 
to detect small but relevant increases in risk. As a conse-
quence, sarcomas were studied as a single outcome and 
not by histological subtypes; at most they were segregated 
into bone sarcomas and soft-tissue sarcomas. Such anal-
yses supported the strong hypothesis that the same aeti-
ology is shared between each subtype and each site. In this 
study, we plan to perform stratified histological subtypes 
analyses. Moreover, since sarcomas may be classified 
into four groups on a molecular basis (ie, sarcomas with 
recurrent translocation, sarcomas with specific activating 
or inactivating mutations, sarcomas with Mouse double 
minute-2 homolog (MDM2) amplifications and sarcomas 
with a complex genomic profile), we will explore the 
feasibility of classifying sarcomas by genetic types instead 
of by histological subtypes for the objective of identifying 
environmental risk factors. The underlying hypothesis is 
that the aetiology among these four molecular groups 
may be homogeneous.
Sensitive analyses will be systematically implemented in 
order to assess the robustness of the produced results and 
to analyse the impact of potential bias (especially selec-
tion bias) on the produced results.
Methods for coordinating the project and for quality control
This study is organised around three different centres or 
committees: a national coordination centre, a steering 
committee and local centres.
The national coordination centre will be in charge of 
running routine operations, assisting participating local 
centres, guaranteeing the quality of the data collection, 
centralising data, supervising the data coding and expo-
sure assessment. Members of this national coordination 
centre will meet on a regular basis (ie, once a week) to 
ensure reactivity to deal with emerging problems and 
to ensure successful project advancement. Exceptional 
meetings will be planned if necessary.
The steering committee’s principal role will be to estab-
lish research priorities based on the availability of the 
data and the current scientific knowledge. The executive 
committee will meet annually to establish or support 
research project. This committee may be supplemented 
by external scientific members in order to obtain advice 
on specific questions.
Local centres will be in charge of determining iden-
tification sources of patients in their districts and of 
collecting data. They will also transmit the collected data 
to the national coordination centre. Local centres will 
include a CRA under the directory of a coordinator.
Standardised procedures are written in a procedure 
manual to specify information circuit and to guarantee 
the quality of the collected data. Besides, a completion 
guide of the standardised questionnaire has been devel-
oped to assist CRA during interviews. These procedure 
manual and completion guide might evolve during the 
study period to deal with emerging problems not planned 
at the protocol step. A data manager will ensure that the 
study is conducted in compliance with the protocol. 
On a regular basis and as frequently as necessary, he/
she will assess the quality of the collected data using 
several indicators: the average time spent by the CRA at 
the subject’s home, the degree of completeness of the 
questionnaires by CRA, the ratio of included patients to 
expected patients the average elapsed time between the 
identification of a patient and the interview, the average 
elapsed time between patient and control interviews and 
so on. Besides, the data manager will detect aberrant 
data, duplication, inaccurate and missing data. Every 
week, these data manager will refer to the head of the 
national coordination centre and report on the progress 
of the study.
All collected data will be centralised in a single location, 
the University of Bordeaux. These data will be informa-
tised by a contractor specialised in health and exposure 
data coding (Centre de Recherche et de Développement 
en Informatique Médicale).
Expected results, as well as possible spin-offs for them
This research is an innovative study that will permit to 
improve scientific knowledge about the aetiology of 
sarcomas and we expect our results to contribute to better 
understand the causes of sarcomas. We will primarily 
address the question of environmental causes, which will 
permit to confirm or generate new hypotheses on the 
environmental risk factors of this disease. This study will 
also provide a unique platform with data that will permit 
to address several research questions other than environ-
mental ones.
This project will also contribute to increase the French 
expertise with regards to research and management of 
sarcomas and will reinforce existing collaboration at a 
national level between each team involved in this study. 
We expect that this study will be a starter for other studies 
at the European/International level in order to create an 
international consortium which will pool original individ-
ual-level data with harmonised data collection and expo-
sure information.
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Patient and public involvement
The development of the design of the study was devel-
oped without patients or public. However, before subject’s 
inclusion, patient associations will be informed about 
setting up of the study and an information note will be 
post in the prefecture of the participating district
EthICs And dIssEMInAtIon
The present study is promoted by the French National 
Institute of Health and Medical Research (identification 
number C17-03). 
Research outputs from this study will be disseminated 
through presentations at national and international 
conferences or workshops and through scientific publica-
tions in peer-reviewed journals.
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